<DOC>
	<DOCNO>NCT01365520</DOCNO>
	<brief_summary>This trial conduct Asia Europe . The aim trial investigate pharmacokinetics ( rate trial drug eliminate body ) single dose turoctocog alfa ( NNC 0155-0000-0004 ( N8 ) ) patient haemophilia A . Participation trial dependent previous participation trial NN7008-3543 ( Part B ) ( NCT00840086 ) .</brief_summary>
	<brief_title>A Single Dose Trial NNC 0155-0000-0004 Patients With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subjects diagnosis severe haemophilia A ( factor VIII le equal 1 % ) Body weight 10 120 kg Subjects complete NN70083543 ( Part B ) subject participate NN70083568 completion NN70083543 ( NCT00840086 ) Known suspect hypersensitivity trial product ( ) relate product Previous participation trial define withdrawal Planned surgery trial period ( catheter , stent , port , dental extraction count surgery exclude subject ) Any disease condition , accord trial physician 's judgement , could imply potential hazard subject , interfere trial participation trial outcome</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>